PMI 8-K
Picard Medical, Inc. (PMI)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices, including zip code) |
Registrant’s telephone number, including
area code: (
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| Item 7.01. | Regulation FD Disclosure. |
On March 12, 2026, Picard Medical, Inc. (the “Company”) issued a press release announcing that the Company will host a webcasted Annual Business Update on March 25, 2026 at 4:30p.m. Eastern Time. As discussed in the press release, the webcast will include management’s review of fiscal year and fourth quarter 2025 financial results and a business overview addressing operational progress, commercial activity, and strategic priorities, as well as perspectives from leading clinicians and a patient testimonial regarding the SynCardia Total Artificial heart. Registration for the webcast is available via a link in the press release furnished herewith as Exhibit 99.1 and is also accessible through the Company’s website at www.picardmedical.com. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
The information in this report and the exhibits attached hereto shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
The following exhibits are being furnished herewith:
| Exhibit No. | Description | |
| 99.1 | Picard Medical, Inc. Press Release dated March 12, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Picard Medical, Inc. | |||
| By: | /s/ Patrick NJ Schnegelsberg | ||
| Name: | Patrick NJ Schnegelsberg | ||
| Title: | Chief Executive Officer | ||
Dated: March 12, 2026
2
Exhibit 99.1
Picard Medical / SynCardia to Host Annual Business Update Featuring Key Opinion Leaders and Patient Testimonial
TUCSON, Ariz., March 12, 2026— Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced it will host an its Annual Business Update virtual call, which will be webcasted, on Wednesday, March 25, 2026 at 4:30 p.m. EDT, following the filing of the Company’s Form 10-K for the fiscal year ended December 31, 2025. The webcast will feature business updates from management, including discussion of the Company’s commercial activities and development of its next-generation, fully implantable total artificial heart platform known as Emperor, as well as perspectives from leading clinicians in the cardiac surgical field and a patient who received the SynCardia Total Artificial Heart (STAH). To register for the event, please click here.
On the webcast, management will provide a review of Picard Medical’s fiscal year and fourth quarter 2025 financial results, along with a business update from management covering operational progress, commercial activity, and strategic priorities. Presentations will be delivered by Patrick NJ Schnegelsberg, Chief Executive Officer; Matthew Schuster, Chief Operating Officer; and Bernard Skaggs, Chief Financial Officer.
The program will include perspectives on implantation of the SynCardia Total Artificial Heart and the evolving artificial heart landscape from leading clinicians, Dr. Zain Khalpey, cardiothoracic surgeon and Surgical Director of the Artificial Heart Program at HonorHealth in Phoenix, and Dr. Amy Fiedler, Associate Professor of Surgery and Surgical Director of Heart Transplantation and Mechanical Circulatory Support at the University of California San Francisco. The event will also feature a patient testimonial reflecting clinical experience with the device.
About Picard Medical and SynCardia
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader
with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops,
manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the circulatory
functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains
the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals
across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world.
For additional information about Picard Medical, please visit www.picardmedical.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements
that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results
to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any
updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with
respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject
to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of
the Registration Statement and related prospectus filed in connection with the initial public offering with the SEC. Copies are available
on the SEC’s website, http://www.sec.gov.
Contact:
Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
[email protected]
Picard Medical, Inc./SynCardia Systems, LLC
[email protected]
General/Media
Brittany Lanza
[email protected]